3rd Annual TRP Target Selection & Drug Design Summit
The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25, 2027, the summit will unite more than 100 experts from across discovery, biology, medicinal chemistry, radiochemistry, ADME/DMPK, toxicology, radiobiology, dosimetry, preclinical development, translational science, and business development.
As established targets such as PSMA become increasingly crowded, the meeting will help radiopharmaceutical developers identify novel targets, explore new disease settings, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs, RDCs, immuno-oncology, and other targeted modalities can be assessed and translated into radioligand therapy programs.
The agenda will explore emerging targets across CAIX, MSLN, the brain, extracellular matrix, and leukocytes, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties, linkers, chelators, radionuclide selection, biodistribution, kinetic imaging, total-body PET, digital SPECT, computational biology, dosimetry, organ-specific toxicity, and preclinical safety strategy.
Two interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference, presentations, roundtables, case studies, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic.
With contributions from experts representing Bayer, AstraZeneca, Molecular Partners, Mariana Oncology, Harvard Medical School, United Theranostics, Ratio Therapeutics, Affibody, and other leading organizations, the summit offers a focused opportunity to improve target selection, strengthen drug design, and build safer, more differentiated radiopharmaceutical pipelines.
To know more visit: https://ter.li/ugtcnsbo
